Earth Science Tech (ETST) Cash from Financing Activities (2011 - 2026)
Earth Science Tech (ETST) posted Cash from Financing Activities of -$44047.0 for Q1 2026, up 76.89% on a QoQ basis from -$190608.0 in Q4 2025, and up 95.47% year-over-year from -$22533.8 in Q1 2025.
Earth Science Tech (ETST) Cash from Financing Activities (2011 - 2026) Analysis & Trends
Earth Science Tech's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$44047.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 95.47% year-over-year to -$44047.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$712917.0 (up 58.44% YoY) and the FY2026 annual result came in at -$712917.0, up 58.44% from the prior year.
- Cash from Financing Activities was -$44047.0 for Q1 2026 at Earth Science Tech, up from -$190608.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $350068.0 in Q1 2023 and bottomed at -$972595.0 in Q1 2025.
- A 5-year average of -$105574.6 and a median of -$86017.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 3065.0% — and 2024, when it plunged 795.24%.
- Earth Science Tech's Cash from Financing Activities stood at $316500.0 in 2022, then plunged by 150.96% to -$161302.0 in 2023, then soared by 218.97% to $191894.0 in 2024, then plunged by 199.33% to -$190608.0 in 2025, then soared by 76.89% to -$44047.0 in 2026.
- Business Quant data shows ETST's Cash from Financing Activities at -$44047.0 in Q1 2026, -$190608.0 in Q4 2025, and -$211459.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Earth Science Tech | 41.03 Mn | 38.90 Mn | 6.27 Mn | -44,047.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44,047.00 |
| Mar 31, 2026 | -44,047.00 |
| Dec 31, 2025 | -190,608.00 |
| Dec 31, 2025 | -190,608.00 |
| Sep 30, 2025 | -211,459.00 |
| Sep 30, 2025 | -211,459.00 |
| Jun 30, 2025 | -266,803.00 |
| Jun 30, 2025 | -266,803.00 |
| Mar 31, 2025 | -972,595.00 |
| Mar 31, 2025 | -972,595.00 |
| Dec 31, 2024 | 191,894.00 |
| Dec 31, 2024 | 191,894.00 |
| Sep 30, 2024 | -770,058.00 |
| Sep 30, 2024 | -770,058.00 |
| Jun 30, 2024 | -164,774.00 |
| Jun 30, 2024 | -164,774.00 |
| Mar 31, 2024 | -380,568.00 |
| Mar 31, 2024 | -380,568.00 |
| Dec 31, 2023 | -161,302.00 |
| Dec 31, 2023 | -161,302.00 |